|
|
||||||||
Ann Thorac Surg 2007;83:1374-1380
© 2007 The Society of Thoracic Surgeons
a Department of Cardiovascular Sciences, Units of Cardiac Surgery and Cardiology, University Campus Bio-Medico, Rome, Italy
b Interdisciplinary Center for Biomedical Research (CIR), University Campus Bio-Medico, Rome, Italy
Accepted for publication October 24, 2006.
* Address correspondence to Dr Chello, Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Via Longoni 83, 00155 Rome, Italy (Email: m.chello{at}unicampus.it).
Background: Neutrophils play a central role in systemic inflammatory reaction after cardiopulmonary bypass. Apoptosis is significantly delayed, and this might exacerbate systemic and myocardial damage. We tested the hypothesis of whether pretreatment with simvastatin increases the apoptotic rate of neutrophils and hence reduces the entity of inflammatory reaction.
Methods: Thirty patients undergoing coronary surgery with cardiopulmonary bypass were randomized to treatment with either simvastatin (40 mg/day) or placebo for 3 weeks before surgery. A group of 15 patients undergoing off-pump coronary surgery served as controls. Blood samples for detection of serum cytokine levels were obtained before anesthesia, at the end of surgery, and at 4, 24, 48, and 72 hours postoperatively. Apoptosis and indices of activation were assessed in cultured neutrophils.
Results: Simvastatin significantly reduced the postoperative peak values of interleukin (IL)-6 and IL-8. The neutrophil apoptotic rate was significantly higher among neutrophils obtained from patients pretreated with simvastatin (p < 0.05 at both 8 and 24 hours) compared with placebo. Neutrophils from the statin group had depressed functional activity, as underscored by significantly lower values of CD11b (p < 0.01 at 24 hours) and a significantly less percentage of cells positive for nitro-blue tetrazolium (p < 0.01 at 12 and 24 hours) compared with placebo.
Conclusions: This randomized, double-blind study indicates that statin therapy before cardiopulmonary bypass is associated with reduction of circulating markers of inflammation and increased neutrophil apoptosis. These data support a routine inclusion of statins as an adjuvant pharmacologic therapy before cardiopulmonary bypass surgery.
This article has been cited by other articles:
![]() |
O. J. Liakopoulos, Y.-H. Choi, P. L. Haldenwang, J. Strauch, T. Wittwer, H. Dorge, C. Stamm, G. Wassmer, and T. Wahlers Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30 000 patients Eur. Heart J., June 2, 2008; 29(12): 1548 - 1559. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dyugovskaya, A. Polyakov, P. Lavie, and L. Lavie Delayed Neutrophil Apoptosis in Patients with Sleep Apnea Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 544 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Shao, Y. Shen, H. Liu, G. Dong, J. Qiang, and H. Jing Simvastatin Suppresses Lung Inflammatory Response in a Rat Cardiopulmonary Bypass Model Ann. Thorac. Surg., December 1, 2007; 84(6): 2011 - 2018. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Namazi Decreasing the Expression of LFA-1 and ICAM-1 as Well as Hindering Their Interaction as the Major Mechanism for Statin-Induced Neutrophil Dysfunction Ann. Thorac. Surg., December 1, 2007; 84(6): 2137 - 2138. [Full Text] [PDF] |
||||
![]() |
M. Thielmann, M. Neuhauser, A. Marr, B. R. Jaeger, D. Wendt, B. Schuetze, M. Kamler, P. Massoudy, R. Erbel, and H. Jakob Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1143 - 1149. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |